Skip to main content

Table 5 Changes of eGFR (ml/min/1.73m2) over time assessed by linear mixed effects models for patients treated with TDF vs. untreated

From: Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study

  Crude model   Adjusted for baseline age, gender, ethnicity
  Coefficient β (95% CI) p-value Coefficient β (95% CI) p-value
(Intercept) 85.813 (84.676, 86.950) < 0.001 93.974 (90.352, 97.595) < 0.001
Group 0.991 (− 1.085, 3.068) 0.349 1.76 (− 0.286, 3.805) 0.092
Time − 0.014 (− 0.050, 0.022) 0.449 −0.016 (− 0.051, 0.019) 0.379
Group x Time a −0.034 (− 0.094, 0.027) 0.278 −0.033 (− 0.092, 0.026) 0.268
  1. a x indicates the interaction between group and follow-up time. Group = {0,1}, where 0 indicates untreated, 1 indicates TDF. CI confidence interval; eGFR estimated glomerular filtration rate; TDF Tenofovir disoproxil fumarate